ESC 365 - LIBerate-HeFH - a novel PCSK9-inhibitor in heterozygous FH

Back

ESC Professional Premium Access

LIBerate-HeFH - a novel PCSK9-inhibitor in heterozygous FH

Session: Late-breaking science on pharmacology

Topic: Drug therapy

Speaker: Professor F. Raal (Johannesburg, ZA)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Professor Frederick Raal

University of the Witwatersrand, Johannesburg (South Africa)

1 presentation

0 follower

3 more presentations in this session

ORION-8: Long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients

Speaker: Professor R. Wright (Rochester, US)

Access

Slides

Video

Muvalaplin, a Potent Small Molecule Inhibitor of Lipoprotein(a)

Speaker: Professor S. Nicholls (Melbourne, AU)

Access

Slides

Video

REMAIN-1: A phase 3 study of recaticimab monotherapy in dyslipidaemia

Speaker: Professor J. Ge (Shanghai, CN)

Access

Slides

Video

Access the full session

Late-breaking science on pharmacology

Speakers: Professor F. Raal, Professor R. Wright, Professor S. Nicholls, Professor J. Ge

Access

Video

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

LIBerate-HeFH - a novel PCSK9-inhibitor in heterozygous FH

About the speaker

Professor Frederick Raal

3 more presentations in this session

ORION-8: Long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients

Muvalaplin, a Potent Small Molecule Inhibitor of Lipoprotein(a)

REMAIN-1: A phase 3 study of recaticimab monotherapy in dyslipidaemia

Access the full session

Late-breaking science on pharmacology

About the event

ESC Congress 2023

ESC 365 is supported by